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Purpose: A variety of dose/fractionation schemes are used for 
adjuvant radiotherapy (RT) in node positive (Stage III) 
melanoma. A prospective randomized study of adjuvant nodal 
radiation for high-risk Stage III melanoma used 2.4 Gy x 20 
fractions in four weeks. The largest retrospective series to date 
used a hypofractionated scheme of 6 Gy x 5 fractions over 2.5 
weeks. No randomized comparison of these has been reported. 
At our institution, either fractionation is used based on physician 
and patient preference. We sought to compare clinical outcomes 
using hypofractionated and conventional radiotherapy for node 
positive melanoma. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan–Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were included in the final analysis. 
Median follow up was two years. Sixty-one percent of patients 
were treated with hypofractionated radiotherapy (6 Gy x 5 for 
23 patients and 6 Gy x 6 for two patients) and the remainder 
received conventional fractionation 40-60 Gy in 15-30 fractions). 
Treatment sites included the axilla (39%), groin (29%) and 
head/neck (32%). No significant differences in stage, number of 
involved nodes, largest node, nodal location, or extracapsular 
extension were present between the two groups. Comparing the 
hypofractionated versus conventional groups, there was no 
significant difference in regional control (76 versus 84%), distant 
control (48 versus 44%) or overall survival (67 versus 62%). 44% 
were referred to a specialty clinic for management of 
lymphedema in the hypofractionated group versus 19% in the 
conventional group (HR 2.56, 95% CI 0.85-7.68, p = 0.094). 
Conclusions: Hypofractionated and conventional radiotherapy 
results in similar rates of disease control at two years in node 
positive melanoma. A trend towards higher referrals for 
lymphedema management was observed in the hypofractionated 
group. Future work should prospectively compare outcomes and 
toxicity for giving patients best advice for hypofractionation 
compared with standard treatment. 
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Purpose: Stage III cutaneous melanoma incorporates a 
heterogeneous patient group with node positive disease. 
Adjuvant radiotherapy decreases regional recurrence but its use 
is sporadic, in part due to a high competing risk of distant failure. 
This study aimed to assess our institutional practice patterns, 
evaluate clinical outcomes post radiotherapy, and identify risk 
factors for distant metastases in Stage III melanoma patients. 
Methods and Materials: Patients who received adjuvant 
radiation for node positive melanoma between 2009 and 2014 
were included. Kaplan-Meier estimates of overall survival (OS) 
and 95% confidence intervals (CI) were obtained. Logistic 
regression was used to explore the association between patient, 
tumour and treatment factors for the outcomes of these 
patients. 
Results: Forty-one patients were analyzed. Median follow up was 
two years. Sixty-one percent presented with palpable nodal 
disease. Sixty-six percent had a sentinel lymph node procedure 
prior to completion nodal dissection. Patients had an average of 
three involved lymph nodes and 23 total lymph nodes removed. 
Extracapsular extension was present in 51% of patients. Sixty-one 
percent of patients received hypofractionated radiotherapy (30 
Gy/5 fractions or 36 Gy/6 fractions over 2.5-3 weeks) versus 39% 
who received conventional fractionation (typically 48 Gy/20 
fractions). Regional radiation targets included the axilla (39%), 
head and neck (32%) and groin (29%). At two years, regional 
control was 82% and distant control was 46%. Median overall 
survival was 3.7 years. All patients who experienced a regional 
failure post-RT developed distant metastases and died of 
melanoma. All patients who were free of distant failure had 
regional control. Development of distant metastases was strongly 
associated with extracapsular extension (HR 4.0, 95% CI 1.8-8.7, 
p < 0.0001). T-stage, N-stage, RT dose, neurotropism, nodal size, 
location and number involved were not associated with regional 
or distant control. 
Conclusions: Patients who receive adjuvant radiotherapy for 
node positive melanoma have high rates of regional control but 
are prone to distant failure. Regional failure is a harbinger of 
distant disease. Extracapsular extension also predicts distant 
failure in this population. 
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Purpose: Prostate cancer resulted in approximately 4100 deaths 
in Canada in 2015. The advent of new systemic agents for 
treatment of metastatic castration-resistant prostate cancer 
demonstrating overall survival benefits has changed the 
landscape of care, and may impact the demand for and provision 
of palliative radiation to bone (PRTB) in this population. The 
purpose is to describe the use of PRTB in patients who died of 
prostate in British Columbia between 2003 and 2015. 
Methods and Materials: All patients that died of prostate cancer 
in the time period were identified from a population-based 
provincial cancer registry. Exclusion criteria included: other sites 
of cancer diagnosis, lack of adenocarcinoma histology, RT to non-
bone sites or of non-palliative intent. Patient and treatment 
characteristics were analyzed using SAS. PRTB use for the first 
and last courses was calculated by year of death, overall, and by 
region. Survival was calculated for the following: from first 
course of PRTB to death, from last course of PRTB to death, and 
by treatment year. To assess the adequacy of provision of PRTB 
in this population, the geographical distribution of the incidence 
of prostate cancer was compared with the treatment frequency 
across the province.  
Results: Out of 23,260 prostate cancer patients who died 
between 2003 and 2015, 5701 had prostate adenocarcinoma as 
their only primary cancer diagnosis. The median age at the time 
of death was 81 and median survival after diagnosis was 5.2 
years. Utilization of PRTB prior to death was 38.6% (2203 
patients), with a trend to increase overtime from 29% in 2003, to 
44% in 2015. Multiple courses of PRTB were frequent, with 
patients receiving two, three, four or more courses of PRTB in 
25%, 13%, and 14% of cases respectively. Survival after first 
course of PRTB to prostate cancer death was 38.6% at one year, 
and 2.3% at five years, and a median of 8.5 months. Median 
survival after first course of PRTB increased slightly over the 
study years for those dying of prostate cancer from 8.2 months 
in 2003-5 to 9.4 months in 2013-15 (p = 0.04). For last course of 
PRTB, 2% were treatment within the last four weeks of their life. 
Use of PRTB varied with region and was lower in some rural 
areas.  
